uniQure Announces Additional Data from Ongoing Phase I/II Studies of ifezuntirgene inilparvovec (AMT-130) in Huntington’s Disease Showing Continued Slowing of Disease Progression

uniQure N.V. (QURE)

We couldn't retrieve the full text for this release. Read it on the company's site.